Search

Your search keyword '"Seitz, Anna Katharina"' showing total 102 results
Start Over "Seitz, Anna Katharina"
102 results on '"Seitz, Anna Katharina"'

1. Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren

Author

Kowalski, Christoph, Sibert, Nora Tabea, Hammerer, Peter, Wesselmann, Simone, Feick, Günter, Carl, Ernst-Günther, Klotz, Theodor, Apel, Hendrik, Dieng, Sebastian, Nyarangi-Dix, Joanne, Knoll, Thomas, Reike, Moritz Johannes, Duwe, Gregor, Bartolf, Elisabeth, Steiner, Thomas, Borowitz, Rainer, Lümmen, Gerd, Seitz, Anna Katharina, Pfitzenmaier, Jesco, Aziz, Atiqullah, Brock, Marko, Berger, Frank Peter, Kaftan, Björn Theodor, Grube, Christian, Häfner, Tim, Hamza, Amir, Schmelz, Hans, Haas, Jürgen, Lenart, Sebastian, Lafita, Anselm, Sippel, Carsten, Winter, Alexander, Kedia, George, Hadaschik, Boris, Varga, Zoltan, Buse, Stephan, Richter, Matthias, Distler, Florian, Simon, Jörg, Wiegel, Thomas, Baltes, Stefan, Janitzky, Andreas, Sommer, Jens Peter, Hijazi, Sameh, Fülkell, Philipp, Harke, Nina N., Bolenz, Christian, Khalil, Christian, Breidenbach, Clara, Tennstedt, Pierre, and Burchardt, Martin

Published
2024
Full Text
View/download PDF

2. SARS-CoV-2 antigen rapid detection tests: test performance during the COVID-19 pandemic and the impact of COVID-19 vaccination

Author

Wagenhäuser, Isabell, Knies, Kerstin, Pscheidl, Tamara, Eisenmann, Michael, Flemming, Sven, Petri, Nils, McDonogh, Miriam, Scherzad, Agmal, Zeller, Daniel, Gesierich, Anja, Seitz, Anna Katharina, Taurines, Regina, Ernestus, Ralf-Ingo, Forster, Johannes, Weismann, Dirk, Weißbrich, Benedikt, Liese, Johannes, Härtel, Christoph, Kurzai, Oliver, Dölken, Lars, Gabel, Alexander, and Krone, Manuel

Published
2024
Full Text
View/download PDF

8. Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database.

Author

Darr, Christopher, primary, Klümper, Niklas, additional, Büttner, Thomas, additional, Holzwarth, Nina, additional, Biernath, Nadine, additional, Höllein, Alexander, additional, Niegisch, Guenter, additional, Seidl, Daniel, additional, Handke, Analena, additional, Paffenholz, Pia, additional, Schlack, Katrin, additional, Cathomas, Richard, additional, Erne, Eva, additional, Banek, Severine, additional, Tauber, Robert, additional, Casuscelli, Jozefina, additional, Seitz, Anna Katharina, additional, Hadaschik, Boris A., additional, Grünwald, Viktor, additional, and Zschaebitz, Stefanie, additional

Published
2024
Full Text
View/download PDF

9. SARS-CoV-2 Antigen Rapid Detection Tests: test performance during the COVID-19 pandemic and the impact of COVID-19 vaccination

Author

Wagenhäuser, Isabell, primary, Knies, Kerstin, additional, Pscheidl, Tamara, additional, Eisenmann, Michael, additional, Flemming, Sven, additional, Petri, Nils, additional, McDonogh, Miriam, additional, Scherzad, Agmal, additional, Zeller, Daniel, additional, Gesierich, Anja, additional, Seitz, Anna Katharina, additional, Taurines, Regina, additional, Ernestus, Ralf-Ingo, additional, Forster, Johannes, additional, Weismann, Dirk, additional, Weißbrich, Benedikt, additional, Liese, Johannes, additional, Härtel, Christoph, additional, Kurzai, Oliver, additional, Dölken, Lars, additional, Gabel, Alexander, additional, and Krone, Manuel, additional

Published
2024
Full Text
View/download PDF

12. Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T

Author

Hartrampf, Philipp E., primary, Hüttmann, Thomas, additional, Seitz, Anna Katharina, additional, Kübler, Hubert, additional, Serfling, Sebastian E., additional, Higuchi, Takahiro, additional, Schlötelburg, Wiebke, additional, Michalski, Kerstin, additional, Gafita, Andrei, additional, Rowe, Steven P., additional, Pomper, Martin G., additional, Buck, Andreas K., additional, and Werner, Rudolf A., additional

Published
2024
Full Text
View/download PDF

13. Reliability of continuous vital sign monitoring in post-operative patients employing consumer-grade fitness trackers: A randomised pilot trial

Author

Helmer, Philipp, primary, Hottenrott, Sebastian, additional, Wienböker, Kathrin, additional, Pryss, Rüdiger, additional, Drosos, Vasileios, additional, Seitz, Anna Katharina, additional, Röder, Daniel, additional, Jovanovic, Aleksandar, additional, Brugger, Jürgen, additional, Kranke, Peter, additional, Meybohm, Patrick, additional, Winkler, Bernd E, additional, and Sammeth, Michael, additional

Published
2024
Full Text
View/download PDF

14. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer

Author

Cytawa, Wojciech, Seitz, Anna Katharina, Kircher, Stefan, Fukushima, Kazuhito, Tran-Gia, Johannes, Schirbel, Andreas, Bandurski, Tomasz, Lass, Piotr, Krebs, Markus, Połom, Wojciech, Matuszewski, Marcin, Wester, Hans-Jürgen, Buck, Andreas K., Kübler, Hubert, and Lapa, Constantin

Published
2020
Full Text
View/download PDF

15. The sensitivity of rapid tests for SARS-CoV-2 antigen

Author

Knies, Kerstin, primary, Wagenhäuser, Isabell, additional, Hofmann, Daniela, additional, Rauschenberger, Vera, additional, Eisenmann, Michael, additional, Reusch, Julia, additional, Flemming, Sven, additional, Andres, Oliver, additional, Petri, Nils, additional, Topp, Max S., additional, Papsdorf, Michael, additional, McDonogh, Miriam, additional, Verma-Führing, Raoul, additional, Scherzad, Agmal, additional, Zeller, Daniel, additional, Böhm, Hartmut, additional, Gesierich, Anja, additional, Seitz, Anna Katharina, additional, Kiderlen, Michael, additional, Gawlik, Micha, additional, Taurines, Regina, additional, Wurmb, Thomas, additional, Ralf-Ingo, -, additional, Ernestus, -, additional, Forster, Johannes, additional, Weismann, Dirk, additional, Weißbrich, Benedikt, additional, Liese, Johannes, additional, Vogel, Ulrich, additional, Kurzai, Oliver, additional, Dölken, Lars, additional, Gabel, Alexander, additional, and Krone, Manuel, additional

Published
2023
Full Text
View/download PDF

17. Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren

Author

Kowalski, Christoph, primary, Sibert, Nora Tabea, additional, Hammerer, Peter, additional, Wesselmann, Simone, additional, Feick, Günter, additional, Carl, Ernst-Günther, additional, Klotz, Theodor, additional, Apel, Hendrik, additional, Dieng, Sebastian, additional, Nyarangi-Dix, Joanne, additional, Knoll, Thomas, additional, Reike, Moritz Johannes, additional, Duwe, Gregor, additional, Bartolf, Elisabeth, additional, Steiner, Thomas, additional, Borowitz, Rainer, additional, Lümmen, Gerd, additional, Seitz, Anna Katharina, additional, Pfitzenmaier, Jesco, additional, Aziz, Atiqullah, additional, Brock, Marko, additional, Berger, Frank Peter, additional, Kaftan, Björn Theodor, additional, Grube, Christian, additional, Häfner, Tim, additional, Hamza, Amir, additional, Schmelz, Hans, additional, Haas, Jürgen, additional, Lenart, Sebastian, additional, Lafita, Anselm, additional, Sippel, Carsten, additional, Winter, Alexander, additional, Kedia, George, additional, Hadaschik, Boris, additional, Varga, Zoltan, additional, Buse, Stephan, additional, Richter, Matthias, additional, Distler, Florian, additional, Simon, Jörg, additional, Wiegel, Thomas, additional, Baltes, Stefan, additional, Janitzky, Andreas, additional, Sommer, Jens Peter, additional, Hijazi, Sameh, additional, Fülkell, Philipp, additional, Harke, Nina N., additional, Bolenz, Christian, additional, Khalil, Christian, additional, Breidenbach, Clara, additional, Tennstedt, Pierre, additional, and Burchardt, Martin, additional

Published
2023
Full Text
View/download PDF

18. Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.

Author

Zschaebitz, Stefanie, Klümper, Niklas, Büttner, Thomas, Holzwarth, Nina, Biernath, Nadine, Höllein, Alexander, Niegisch, Guenter, Seidl, Daniel, Aydogdu, Can, Handke, Analena, Paffenholz, Pia, Schlack, Katrin, Cathomas, Richard, Erne, Eva, Banek, Severine, Tauber, Robert, Casuscelli, Jozefina, Seitz, Anna Katharina, Grünwald, Viktor, and Darr, Christopher

Published
2024
Full Text
View/download PDF

20. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Directed Radioligand Therapy

Author

Hartrampf, Philipp E., primary, Mihatsch, Patrick W., additional, Seitz, Anna Katharina, additional, Solnes, Lilja B., additional, Rowe, Steven P., additional, Pomper, Martin G., additional, Kübler, Hubert, additional, Bley, Thorsten A., additional, Buck, Andreas K., additional, and Werner, Rudolf A., additional

Published
2023
Full Text
View/download PDF

22. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T.

Author

Hartrampf, Philipp E., Hüttmann, Thomas, Seitz, Anna Katharina, Kübler, Hubert, Serfling, Sebastian E., Schlötelburg, Wiebke, Michalski, Kerstin, Rowe, Steven P., Pomper, Martin G., Buck, Andreas K., Eberlein, Uta, and Werner, Rudolf A.

Subjects
PROSTATE cancer patients, LUTEINIZING hormone releasing hormone, C-reactive protein, ASPARTATE aminotransferase, OVERALL survival, LACTATE dehydrogenase, ALKALINE phosphatase, PROGNOSIS
Abstract

Background: Quantification of [68 Ga]-labeled PSMA PET predicts response in patients with prostate cancer (PC) who undergo PSMA-targeted radioligand therapy (RLT). Given the increasing use [18F]-labeled radiotracers, we aimed to determine whether the uptake derived from [18F]PSMA-1007 PET can also identify responders and to assess its prognostic value relative to established clinical parameters. Methods: We retrospectively analyzed 103 patients with metastatic, castration-resistant PC who were treated with [177Lu]Lu-PSMA I&T. We calculated SUVmean, SUVmax, PSMA-avid tumor volume (TV), and total lesion PSMA (defined as PSMA-TV*SUVmean) on pre-therapeutic [18F]PSMA-1007 PET. Laboratory values for hemoglobin, C-reactive protein (CRP), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alkaline phosphatase (AP) were also collected prior to RLT. We performed univariable Cox regression followed by multivariable and Kaplan–Meier analyses with overall survival (OS) serving as endpoint. Last, we also computed a risk factor (RF) model including all items reaching significance on multivariable analysis to determine whether an increasing number of RFs can improve risk stratification. Results: A total of 48 patients died and median OS was 16 months. On univariable Cox regression, SUVmean, CRP, LDH, hemoglobin, and the presence of liver metastases were significantly associated with OS. On multivariable Cox regression, the following significant prognostic factors for OS were identified: SUVmean (per unit, HR, 0.91; P = 0.04), the presence of liver metastases (HR, 2.37; P = 0.03), CRP (per mg/dl, HR, 1.13; P = 0.003), and hemoglobin (per g/dl, HR, 0.76; P < 0.01). Kaplan–Meier analysis showed significant separation between patients with a SUVmean below or above a median SUVmean of 9.4 (9 vs 19 months, HR 0.57; P = 0.03). Of note, patients with only one RF (median OS not reached) showed longest survival compared to patients with two (11 months; HR 2.43 95% CI 1.07–5.49, P = 0.02) or more than two RFs (7 months; HR 3.37 95% CI 1.62–7.03, P < 0.001). Conclusion: A lower SUVmean derived from [18F]PSMA-1007, higher CRP, lower hemoglobin, and the presence of liver metastases are associated with reduced OS in patients undergoing RLT. An early RF model also demonstrated that an increasing number of those factors is linked to worse outcome, thereby emphasizing the importance of clinical and imaging parameters for adequate risk stratification. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Ein Propensity-Score-Vergleich im Hinblick auf chirurgische, renale und funktionelle Ergebnisse von Ileozökalpouch-Patient/innen mit benigner versus Urothelkarzinom als Grunderkrankung

Author

Schwinger, Marcel, Seitz, Anna-Katharina, Kübler, Hubert, Kocot, Arkadius, and Kalogirou, Charis

Subjects
ddc: 610, Medicine and health
Abstract

Einleitung: Für die Entscheidung, ob Betroffene mit einer chronischen benignen Blasenerkrankung von einer kontinenten kutanen Harnableitung (CCUD) profitieren, konnten bisher nur wenige Studien herangezogen werden. Diese Arbeit soll mittels eines Propensity-Score basierten Ansatzes überprüfen, [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022

25. Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach

Author

Hartrampf, Philipp E., primary, Krebs, Markus, additional, Peter, Lea, additional, Heinrich, Marieke, additional, Ruffing, Julia, additional, Kalogirou, Charis, additional, Weinke, Maximilian, additional, Brumberg, Joachim, additional, Kübler, Hubert, additional, Buck, Andreas K., additional, Werner, Rudolf A., additional, and Seitz, Anna Katharina, additional

Published
2022
Full Text
View/download PDF

27. Virus Variant Specific Clinical Performance Assessment of SARS-CoV-2 Rapid Antigen Tests in Point-of-Care Use Including Omicron VOC

Author

Wagenhäuser, Isabell, primary, Knies, Kerstin, additional, Hofmann, Daniela, additional, Rauschenberger, Vera, additional, Eisenmann, Michael, additional, Gabel, Alexander, additional, Flemming, Sven, additional, Andres, Oliver, additional, Petri, Nils, additional, Topp, Max S., additional, Papsdorf, Michael, additional, McDonogh, Miriam, additional, Verma-Führing, Raoul, additional, Scherzad, Agmal, additional, Zeller, Daniel, additional, Böhm, Hartmut, additional, Gesierich, Anja, additional, Seitz, Anna Katharina, additional, Kiderlen, Michael, additional, Gawlik, Micha, additional, Taurines, Regina, additional, Forster, Johannes, additional, Weismann, Dirk, additional, Weißbrich, Benedikt, additional, Dölken, Lars, additional, Liese, Johannes G., additional, Kurzai, Oliver, additional, Vogel, Ulrich, additional, and Krone, Manuel, additional

Published
2022
Full Text
View/download PDF

30. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up.

Author

Hartrampf, Philipp E., Seitz, Anna Katharina, Weinzierl, Franz-Xaver, Serfling, Sebastian E., Schirbel, Andreas, Rowe, Steven P., Kübler, Hubert, Buck, Andreas K., and Werner, Rudolf A.

Subjects
*PROSTATE-specific membrane antigen, *PROSTATE cancer treatment, *LACTATE dehydrogenase, *CLINICAL trials, *REGRESSION analysis
Abstract

Background: Radioligand therapy (RLT) with 177Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [177Lu]Lu-PSMA I&T RLT in a long-term follow-up. Materials and methods: Ninety-two mCRPC patients treated with [177Lu]Lu-PSMA I&T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, prior therapies, and time interval between initial diagnosis and first treatment cycle (intervalDiagnosis-RLT, per 12 months). Cutoff values for significant predictors were determined using receiver operating characteristic (ROC) analysis. ROC-derived thresholds were then applied to Kaplan–Meier analyses. Results: Baseline C-reactive protein (CRP; hazard ratio [HR], 1.10, 95% CI 1.02–1.18; P = 0.01), lactate dehydrogenase (LDH; HR, 1.07, 95% CI 1.01–1.11; P = 0.01), aspartate aminotransferase (AST; HR, 1.16, 95% CI 1.06–1.26; P = 0.001), and intervalDiagnosis-RLT (HR, 0.95, 95% CI 0.91–0.99; P = 0.02) were identified as independent prognostic factors for OS. The following respective ROC-based thresholds were determined: CRP, 0.98 mg/dl (area under the curve [AUC], 0.80); LDH, 276.5 U/l (AUC, 0.83); AST, 26.95 U/l (AUC, 0.73); and intervalDiagnosis-RLT, 43.5 months (AUC, 0.68; P < 0.01, respectively). Respective Kaplan–Meier analyses demonstrated a significantly longer median OS of patients with lower CRP, lower LDH, and lower AST, as well as prolonged intervalDiagnosis-RLT (P ≤ 0.01, respectively). Conclusion: In mCRPC patients treated with [177Lu]Lu-PSMA I&T, baseline CRP, LDH, AST, and time interval until RLT initiation (thereby reflecting a possible indicator for tumor aggressiveness) are independently associated with survival. Our findings are in line with previous findings on [177Lu]Lu-PSMA-617, and we believe that these clinical baseline characteristics may support the nuclear medicine specialist to identify long-term survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.

Author

Cytawa, Wojciech, Kircher, Stefan, Kübler, Hubert, Werner, Rudolf A., Weber, Simon, Hartrampf, Philipp, Bandurski, Tomasz, Lass, Piotr, Połom, Wojciech, Matuszewski, Marcin, Wester, Hans-Jürgen, Lapa, Constantin, Rosenwald, Andreas, Seitz, Anna Katharina, and Buck, Andreas K.

Subjects
COMPUTED tomography, PROSTATE cancer, POSITRON emission tomography, RADICAL prostatectomy, LYMPHATIC metastasis, IMMUNOSTAINING
Abstract

Purpose: The purpose of this study was to immunohistochemically validate the primary tumor PSMA expression in prostate cancer (PCa) patients imaged with [68Ga]Ga-PSMA PET/CT prior to surgery, with special consideration of PET-negative cases. Methods: The study included 40 men with newly diagnosed treatment-naïve PCa imaged with [68Ga]Ga-PSMA I&T PET/CT as part of the diagnostic work-up prior to radical prostatectomy. All primary tumors were routinely stained with H&E. In addition, immunohistochemical staining of PSMA was performed and the immunoreactive score (IRS) was computed as semiquantitative measure. Subsequently, imaging findings were correlated to histopathologic results. Results: Eighty-three percent (33/40) of patients presented focal uptake of [68Ga]Ga-PSMA I&T in the primary tumor in at least one prostate lobe. Among PSMA-PET positive patients, one-third had lymph node metastases (LNM) detected by post-operative histopathology, while in PET negative patients, only 1 out of 7 presented with regional LN involvement; PSMA-avid distant lesions, predominantly in bones, were observed in 15% and 0% of patients, respectively. The median IRS classification of PSMA expression in tumor tissue was 2 (range, 1–3) both in PSMA-PET positive and negative prostate lobes, with significantly different interquartile range: 2–3 vs. 2–2, respectively (p = 0.03). The median volume of PSMA-PET positive tumors was 5.4 mL (0.2–32.9) as compared to 1.6 mL (0.3–18.3) of PET-negative tumors (p < 0.001). There was a significant but weak correlation between SUVmax and percentage of PSMA-positive tumor cells (r = 0.46, p < 0.001). A total of 35/44 (~80%) lobes were positive in PSMA-PET imaging, when a cut-off percentage of PSMA-positive cells was ≥ 90%, while 19/36 (~53%) lobes with < 90% PSMA-positive cells were PSMA-PET negative. Conclusion: Positive [68Ga]Ga-PSMA I&T PET/CT scan of primary tumor of PCa results from a combination of factors, such as homogeneity and intensity of PSMA expression, tumor volume and grade, with a cutoff value of ≥ 90% PSMA-positive cells strongly determining PET-positivity. Focal accumulation of [68Ga]Ga-PSMA in the primary tumor may correlate positively with aggressiveness of prostate cancer, harboring higher risk of regional LN involvement and distant metastatic spread. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Author

Hartrampf, Philipp E., Weinzierl, Franz-Xaver, Buck, Andreas K., Rowe, Steven P., Higuchi, Takahiro, Seitz, Anna Katharina, Kübler, Hubert, Schirbel, Andreas, Essler, Markus, Bundschuh, Ralph A., and Werner, Rudolf A.

Subjects
CASTRATION-resistant prostate cancer, PROSTATE-specific antigen, NEPHROTOXICOLOGY
Abstract

Background: Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT. Materials and methods: A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [177Lu]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [177Lu]Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared. Results: Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for [177Lu]Lu-PSMA I&T and five (9.1%) for [177Lu]Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for [177Lu]Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with [177Lu]Lu-PSMA I&T did not differ significantly when compared to patients treated with [177Lu]Lu-PSMA-617 (median OS, 13 months; P = 0.89). Conclusion: In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy — Do Different Software Solutions Deliver Comparable Results?

Author

Hartrampf, Philipp E., Heinrich, Marieke, Seitz, Anna Katharina, Brumberg, Joachim, Sokolakis, Ioannis, Kalogirou, Charis, Schirbel, Andreas, Kübler, Hubert, Buck, Andreas K., Lapa, Constantin, and Krebs, Markus

Subjects
total lesion PSMA, software, lcsh:R, biomarker, lcsh:Medicine, comparability, Prostate-specific membrane antigen (PSMA), metabolic tumour volume (MTV), ddc:610, urologic and male genital diseases, agreement, Article
Abstract

(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: 68Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland–Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.

Published
2020

35. Detection rate of 68Ga-PSMA Ligand PET/CT in patients with recurrent prostate cancer and androgen deprivation therapy

Author

Brumberg, Joachim, Beckl, Melanie, Dierks, Alexander, Schirbel, Andreas, Krebs, Markus, Buck, Andreas, Kübler, Hubert, Lapa, Constantin, and Seitz, Anna Katharina

Subjects
detection rate, recurrent prostate cancer, lcsh:Biology (General), 68Ga-PSMA ligand PET/CT, androgen deprivation therapy, ddc:610, urologic and male genital diseases, lcsh:QH301-705.5, Article
Abstract

Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of 68Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and 68Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All 68Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, p = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (p &lt, 0.01) and PSMA-derived tumor volume (p &lt, 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels &lt, 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended.

Published
2020

38. Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?

Author

Hartrampf, Philipp E., primary, Heinrich, Marieke, additional, Seitz, Anna Katharina, additional, Brumberg, Joachim, additional, Sokolakis, Ioannis, additional, Kalogirou, Charis, additional, Schirbel, Andreas, additional, Kübler, Hubert, additional, Buck, Andreas K., additional, Lapa, Constantin, additional, and Krebs, Markus, additional

Published
2020
Full Text
View/download PDF

39. Diagnostische Wertigkeit der 68Gallium-PSMA PET/CT zu Beurteilung des Therapieansprechens von Patienten mit metastasiertem Prostatakarzinom unter Docetaxel-Chemotherapie

Author

Seitz, Anna Katharina, Rauscher, Isabel, Haller, Bernhard, Kroenke, Markus, Luther, Sophia, Heck, Matthias, Horn, Thomas, Gschwend, Jürgen, Schwaiger, Markus, Eiber, Matthias, and Maurer, Tobias

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Aussagekraft der konventionellen Bildgebung zur Beurteilung des Therapieansprechens bei Patienten mit metastasiertem Prostatakarzinom (PC) unter Systemtherapie ist limitiert. Insbesondere die Abgrenzung einer Tumorprogression gegenüber therapieassoziierten Effekten gestaltet sich[zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. gemeinsamen Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2018

41. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer

Author

Cytawa, Wojciech, primary, Seitz, Anna Katharina, additional, Kircher, Stefan, additional, Fukushima, Kazuhito, additional, Tran-Gia, Johannes, additional, Schirbel, Andreas, additional, Bandurski, Tomasz, additional, Lass, Piotr, additional, Krebs, Markus, additional, Połom, Wojciech, additional, Matuszewski, Marcin, additional, Wester, Hans-Jürgen, additional, Buck, Andreas K., additional, Kübler, Hubert, additional, and Lapa, Constantin, additional

Published
2019
Full Text
View/download PDF

43. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.

Author

Cytawa, Wojciech, Seitz, Anna Katharina, Kircher, Stefan, Fukushima, Kazuhito, Tran-Gia, Johannes, Schirbel, Andreas, Bandurski, Tomasz, Lass, Piotr, Krebs, Markus, Połom, Wojciech, Matuszewski, Marcin, Wester, Hans-Jürgen, Buck, Andreas K., Kübler, Hubert, and Lapa, Constantin

Subjects
*PROSTATE cancer, *POSITRON emission tomography computed tomography, *TUMOR classification, *EXOCRINE glands, *LYMPHADENECTOMY, *PROSTATE-specific membrane antigen, *GLEASON grading system
Abstract

Purpose: The present study is based on a retrospective analysis of Gallium-68 (68Ga)-labelled prostate-specific membrane antigen (68Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment. Methods: A total of 82 men were included in the study and were imaged with 68Ga-PSMA I&T PET/CT to assess the distribution of PSMA-avid disease for staging purposes (11 with low-risk, 32 with intermediate-risk, and 39 with high-risk PCa). Forty patients (20 with intermediate- and 20 with high-risk disease) underwent subsequent radical prostatectomy with extended pelvic lymph node dissection which allowed for correlation of imaging findings with histopathologic data. Results: PSMA-positive disease was detected in 83% of patients with 66/82 (80.5%) primary tumours being visualized. PSMA-avid lymph nodes were recorded in 17/82 patients (20.7%, 3 with intermediate-risk and 14 with high-risk PCa); distant disease was found in 14/82 subjects (17.1%, 2 with intermediate-risk and 12 with high-risk PCa). No extraprostatic disease was found in low-risk PCa. SUVmax of primary tumours showed a weak but significant correlation with serum PSA values (r = 0.51, p < 0.001) and Gleason scores (GSC; r = 0.35, p = 0.001), respectively. In correlation with histopathology, calculated per-region sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of lymph node metastases were 35.0%, 98.4%, 63.6%, 95.0%, and 93.0%, respectively. Conclusions: In patients with initial diagnosis of intermediate- and high-risk prostate cancer, 68Ga-PSMA I&T PET/CT emerges as a relevant staging procedure by identifying nodal and/or distant metastases. Due to the low prevalence of extraprostatic disease, its value seems to be limited in low-risk disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. PD14-03 PREDICTION OF TREATMENT RESISTANCE UNDER ABIRATERONE AND ENZALUTMIDE VIA DETECTION OF AR-V7 IN PERIPHERAL WHOLE BLOOD OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

Author

Seitz, Anna-Katharina, primary, Thoene, Silvia, additional, Bietenbeck, Andreas, additional, Nawroth, Roman, additional, Tauber, Robert, additional, Thalgott, Mark, additional, Schmid, Sebastian, additional, Secci, Ramona, additional, Retz, Margitta, additional, Gschwend, Jürgen, additional, Ruland, Jürgen, additional, Winter, Christof, additional, and Heck, Matthias, additional

Published
2018
Full Text
View/download PDF

45. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy

Author

Seitz, Anna Katharina, primary, Rauscher, Isabel, additional, Haller, Bernhard, additional, Krönke, Markus, additional, Luther, Sophia, additional, Heck, Matthias M., additional, Horn, Thomas, additional, Gschwend, Jürgen E., additional, Schwaiger, Markus, additional, Eiber, Matthias, additional, and Maurer, Tobias, additional

Published
2017
Full Text
View/download PDF

46. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Author

Seitz, Anna Katharina, primary, Thoene, Silvia, additional, Bietenbeck, Andreas, additional, Nawroth, Roman, additional, Tauber, Robert, additional, Thalgott, Mark, additional, Schmid, Sebastian, additional, Secci, Ramona, additional, Retz, Margitta, additional, Gschwend, Jürgen E., additional, Ruland, Jürgen, additional, Winter, Christof, additional, and Heck, Matthias M., additional

Published
2017
Full Text
View/download PDF

47. Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin

Author

Schmid, Sebastian C., primary, Sathe, Anuja, additional, Guerth, Ferdinand, additional, Seitz, Anna-Katharina, additional, Heck, Matthias M., additional, Maurer, Tobias, additional, Schwarzenböck, Sarah M., additional, Krause, Bernd J., additional, Schulz, Wolfgang A., additional, Stoehr, Robert, additional, Gschwend, Jürgen E., additional, Retz, Margitta, additional, and Nawroth, Roman, additional

Published
2017
Full Text
View/download PDF

48. Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer

Author

Seitz, Anna Katharina, primary, Christensen, Lise Lotte, additional, Christensen, Emil, additional, Faarkrog, Kasper, additional, Ostenfeld, Marie Stampe, additional, Hedegaard, Jakob, additional, Nordentoft, Iver, additional, Nielsen, Morten Muhlig, additional, Palmfeldt, Johan, additional, Thomson, Michelle, additional, Jensen, Michael Theis Solgaard, additional, Nawroth, Roman, additional, Maurer, Tobias, additional, Ørntoft, Torben Falck, additional, Jensen, Jørgen Bjerggaard, additional, Damgaard, Christian Kroun, additional, and Dyrskjøt, Lars, additional

Published
2017
Full Text
View/download PDF

49. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

Author

Hedegaard, Jakob, Lamy, Philippe, Nordentoft, Iver, Algaba, Ferran, Hoyer, Soren, Ulhoi, Benedicte Parm, Vang, Soren, Reinert, Thomas, Hermann, Gregers G., Mogensen, Karin, Thomsen, Mathilde Borg Houlberg, Nielsen, Morten Muhlig, Marquez, Mirari, Segersten, Ulrika, Aine, Mattias, Hoglund, Mattias, Birkenkamp-Demtroder, Karin, Fristrup, Niels, Borre, Michael, Hartmann, Arndt, Stoehr, Robert, Wach, Sven, Keck, Bastian, Seitz, Anna Katharina, Nawroth, Roman, Maurer, Tobias, Tulic, Cane, Simic, Tatjana, Junker, Kerstin, Horstmann, Marcus, Harving, Niels, Petersen, Astrid Christine, Luz Calle, M., Steyerberg, Ewout W., Beukers, Willemien, van Kessel, Kim E. M., Jensen, Jorgen Bjerggaard, Pedersen, Jakob Skou, Malmström, Per-Uno, Malats, Nuria, Real, Francisco X., Zwarthoff, Ellen C., Orntoft, Torben Falck, Dyrskjot, Lars, Hedegaard, Jakob, Lamy, Philippe, Nordentoft, Iver, Algaba, Ferran, Hoyer, Soren, Ulhoi, Benedicte Parm, Vang, Soren, Reinert, Thomas, Hermann, Gregers G., Mogensen, Karin, Thomsen, Mathilde Borg Houlberg, Nielsen, Morten Muhlig, Marquez, Mirari, Segersten, Ulrika, Aine, Mattias, Hoglund, Mattias, Birkenkamp-Demtroder, Karin, Fristrup, Niels, Borre, Michael, Hartmann, Arndt, Stoehr, Robert, Wach, Sven, Keck, Bastian, Seitz, Anna Katharina, Nawroth, Roman, Maurer, Tobias, Tulic, Cane, Simic, Tatjana, Junker, Kerstin, Horstmann, Marcus, Harving, Niels, Petersen, Astrid Christine, Luz Calle, M., Steyerberg, Ewout W., Beukers, Willemien, van Kessel, Kim E. M., Jensen, Jorgen Bjerggaard, Pedersen, Jakob Skou, Malmström, Per-Uno, Malats, Nuria, Real, Francisco X., Zwarthoff, Ellen C., Orntoft, Torben Falck, and Dyrskjot, Lars

Abstract

Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into three major classes with basal-and luminal-like characteristics and different clinical outcomes. Large differences in biological processes such as the cell cycle, epithelial-mesenchymal transition, and differentiation were observed. Analysis of transcript variants revealed frequent mutations in genes encoding proteins involved in chromatin organization and cytoskeletal functions. Furthermore, mutations in well-known cancer driver genes (e.g., TP53 and ERBB2) were primarily found in high-risk tumors, together with APOBEC-related mutational signatures. The identification of subclasses in NMIBC may offer better prognostication and treatment selection based on subclass assignment.

Published
2016
Full Text
View/download PDF

50. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

Author

Hedegaard, Jakob, primary, Lamy, Philippe, additional, Nordentoft, Iver, additional, Algaba, Ferran, additional, Høyer, Søren, additional, Ulhøi, Benedicte Parm, additional, Vang, Søren, additional, Reinert, Thomas, additional, Hermann, Gregers G., additional, Mogensen, Karin, additional, Thomsen, Mathilde Borg Houlberg, additional, Nielsen, Morten Muhlig, additional, Marquez, Mirari, additional, Segersten, Ulrika, additional, Aine, Mattias, additional, Höglund, Mattias, additional, Birkenkamp-Demtröder, Karin, additional, Fristrup, Niels, additional, Borre, Michael, additional, Hartmann, Arndt, additional, Stöhr, Robert, additional, Wach, Sven, additional, Keck, Bastian, additional, Seitz, Anna Katharina, additional, Nawroth, Roman, additional, Maurer, Tobias, additional, Tulic, Cane, additional, Simic, Tatjana, additional, Junker, Kerstin, additional, Horstmann, Marcus, additional, Harving, Niels, additional, Petersen, Astrid Christine, additional, Calle, M. Luz, additional, Steyerberg, Ewout W., additional, Beukers, Willemien, additional, van Kessel, Kim E.M., additional, Jensen, Jørgen Bjerggaard, additional, Pedersen, Jakob Skou, additional, Malmström, Per-Uno, additional, Malats, Núria, additional, Real, Francisco X., additional, Zwarthoff, Ellen C., additional, Ørntoft, Torben Falck, additional, and Dyrskjøt, Lars, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results